Dova Pharmaceuticals is a clinical-stage pharmaceutical company focused on acquiring, developing, and marketing treatments for thrombocytopenia, a disorder characterized by a low blood platelet count. The Company's major drug candidate, avatrombopag, is an orally administered thrombopoietin receptor agonist.
Dova has recently completed two identically designed pivotal Phase 3 clinical trials that evaluated avatrombopag for the treatment of thrombocytopenia in patients with chronic liver disease, or CLD, undergoing non-emergent minimally to moderately invasive medical procedures.
Net income (FY, 2016)
EBIT (FY, 2016)
Market capitalization (22-Jun-2018)
Closing share price (22-Jun-2018)
General and administrative expense
Operating expense total
Cash From Operating Activities
Cash From Financing Activities